Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-counter pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009.

3 Feb 2010

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

Entelos, Inc., a simulation and modeling company focused on human health, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,654,955 entitled “Apparatus and Methods for Assessing Metabolic Substrate Utilization” to the Company. These methods further strengthen the Entelos® Metabolism PhysioLab® platform and leverage insights about human physiology that can lead to improved diagnosis, clinical testing, and personalized treatment across a highly variable patient population.

2 Feb 2010

FDA approves INNOPHARMA's ibutilide fumarate injection ANDA

INNOPHARMA LLC announced today FDA approval of the Abbreviated New Drug Application (ANDA) for ibutilide fumarate injection (the generic equivalent of Corvert® from Pfizer Inc).

2 Feb 2010

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Compugen Ltd. announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders.

2 Feb 2010

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration today approved Xiaflex (collagenase clostridium histolyticum) as the first drug to treat a progressive hand disease known as Dupuytren's contracture, which can affect a person's ability to straighten and properly use their fingers.

2 Feb 2010

Isogenica, Phylogica partner in Phylomer peptide development

Isogenica Ltd today announced that it has entered into an agreement with Australian based biopharmaceutical company Phylogica to use Isogenica’s CIS display technology to optimize the performance of three of Phylogica’s lead compounds targeting CD40 ligand (CD40L). CD40L is a key protein involved in many inflammatory diseases, such as Rheumatoid Arthritis and Inflammatory Bowel Disease.

2 Feb 2010

MDLinx announces new Omnibus offering for international pharmaceutical market research

MDLinx, a division of M3 USA, announced today a new Omnibus offering for international pharmaceutical market research. The new offering, launched at the Pharmaceutical Market Research Conference, enables market researchers a new, simplified, reduced-cost means of accessing specialty physicians around the world.

2 Feb 2010

BRI partners with French Government to create therapeutic antibodies for treatment of major diseases

"We are delighted to be working with such esteemed institutions in order to generate cutting-edge therapeutic antibodies," said Matthew Baker, chief scientific officer and co-founder of Antitope. "This agreement combines our partners' expertise in novel therapeutic strategies with Antitope's expertise in engineering humanized antibodies to create therapeutic antibodies that may have a significant impact on the treatment of these major diseases."

2 Feb 2010

Researchers identify antiviral small molecule that is effective against numerous viruses

Viruses are insidious creatures. They differ from each other in many ways, and they can mutate - at times seemingly at will, as with HIV - to resist a host of weapons fired at them. Complicating matters further is that new viruses are constantly emerging.

2 Feb 2010

New biomarker may predict treatment outcomes in RA patients

Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.

30 Jan 2010

Arthritis pain relief drug ALEVE now available OTC in British Columbia

This winter, British Columbians may be inspired to increase their activity level and take part in some favourite winter pastimes. For those who have joint and arthritis pain, getting back to doing the activities they love may be more of a challenge. ALEVE(R) is the first over-the-counter naproxen sodium tablet, and is now available province-wide. With just one pill, ALEVE(R) offers convenient access to pain relief for up to 12 hours.

29 Jan 2010

Nontoxic drug halts and reverses rheumatoid arthritis

A researcher from Northwestern University Feinberg School of Medicine has invented a novel way to halt and even reverse rheumatoid arthritis. He developed an imitation of a suicide molecule that floats undetected into overactive immune cells responsible for the disease.

29 Jan 2010

VisEn Medical acquires Bayer Schering Pharma AG's fluorescence agent intellectual property portfolios

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that it has acquired the fluorescence imaging agent intellectual property portfolios and related technology platforms from Bayer Schering Pharma AG, Germany.

29 Jan 2010

New technique could eliminate hip replacement surgeries in young trauma patients

A novel surgery using transplanted bone and cartilage may help young patients avoid a hip replacement after a specific traumatic injury to the hip joint, according to a case study by orthopedic trauma specialists at Hospital for Special Surgery in New York. The study appears in the February issue of the Journal of Orthopaedic Trauma.

28 Jan 2010

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.

28 Jan 2010

Automated measurements more reliable in moderate cases of knee degeneration

Scientists have automated the measurement of a vital part of the knee in images with a computer program that performs much faster and just as reliably as humans who interpret the same images.

28 Jan 2010

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development.

28 Jan 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

FDA approves INNOPHARMA's ibutilide fumarate injection ANDA

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

Isogenica, Phylogica partner in Phylomer peptide development

MDLinx announces new Omnibus offering for international pharmaceutical market research

BRI partners with French Government to create therapeutic antibodies for treatment of major diseases

Researchers identify antiviral small molecule that is effective against numerous viruses

New biomarker may predict treatment outcomes in RA patients

Arthritis pain relief drug ALEVE now available OTC in British Columbia

Nontoxic drug halts and reverses rheumatoid arthritis

VisEn Medical acquires Bayer Schering Pharma AG's fluorescence agent intellectual property portfolios

New technique could eliminate hip replacement surgeries in young trauma patients

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Celgene reports total revenue of $758M for fourth-quarter of 2009

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Automated measurements more reliable in moderate cases of knee degeneration

Pfizer's new pipeline shows growth and diversity in research and development

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in